BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22510495)

  • 21. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
    Reck M; Heigener DF; Gatzemeier U
    Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pemetrexed].
    Sudoh J; Gemma A
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):1033-8. PubMed ID: 18633241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pemetrexed therapy for malignant pleural mesothelioma.
    Puto K; Garey JS
    Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pemetrexed-cisplatin combination in mesothelioma.
    Reck M; Gatzemeier U
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):231-7. PubMed ID: 15877521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of failure following surgical resection for malignant pleural mesothelioma.
    Jänne PA; Baldini EH
    Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.
    Reck M; Stahel RA; von Pawel J; Karthaus M; Korfee S; Serke M; Schuette WH; Eschbach C; Fink TH; Leschinger MI; Manegold C
    Respir Med; 2010 Jan; 104(1):142-8. PubMed ID: 19818589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Monte Carlo approach for change-point detection in the Cox proportional hazards model.
    Liu M; Lu W; Shao Y
    Stat Med; 2008 Aug; 27(19):3894-909. PubMed ID: 18254131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option.
    Razak AR; Chatten KJ; Hughes AN
    Lung Cancer; 2008 May; 60(2):294-7. PubMed ID: 17919769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
    Kuribayashi K; Voss S; Nishiuma S; Arakawa K; Nogi Y; Mikami K; Kudoh S
    Lung Cancer; 2012 Mar; 75(3):353-9. PubMed ID: 21890228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia.
    Hasani A; Feeney K; Nowak A; Millward M
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):350-6. PubMed ID: 21114785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Malignant pleural mesothelioma: current concepts in treatment.
    Tsiouris A; Walesby RK
    Nat Clin Pract Oncol; 2007 Jun; 4(6):344-52. PubMed ID: 17534390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
    Li L; Razak AR; Hughes A
    Lung Cancer; 2009 May; 64(2):207-10. PubMed ID: 18926592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
    J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma.
    Favoni RE; Florio T
    Trends Pharmacol Sci; 2011 Aug; 32(8):463-79. PubMed ID: 21620489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
    Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study.
    Urba S; van Herpen CM; Sahoo TP; Shin DM; Licitra L; Mezei K; Reuter C; Hitt R; Russo F; Chang SC; Hossain AM; Frimodt-Moller B; Koustenis A; Hong RL
    Cancer; 2012 Oct; 118(19):4694-705. PubMed ID: 22434360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weighted Kaplan-Meier estimators for two-stage treatment regimes.
    Miyahara S; Wahed AS
    Stat Med; 2010 Nov; 29(25):2581-91. PubMed ID: 20799259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statistical power in parallel group point exposure studies with time-to-event outcomes: an empirical comparison of the performance of randomized controlled trials and the inverse probability of treatment weighting (IPTW) approach.
    Austin PC; Schuster T; Platt RW
    BMC Med Res Methodol; 2015 Oct; 15():87. PubMed ID: 26472109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.